Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Stock Position Increased by Vanguard Group Inc.

Vanguard Group Inc. raised its position in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) by 5.1% in the third quarter, HoldingsChannel reports. The firm owned 1,474,879 shares of the biotechnology company’s stock after acquiring an additional 70,912 shares during the period. Vanguard Group Inc.’s holdings in Alpine Immune Sciences were worth $16,887,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of ALPN. Bank of New York Mellon Corp boosted its position in shares of Alpine Immune Sciences by 1.3% during the third quarter. Bank of New York Mellon Corp now owns 92,723 shares of the biotechnology company’s stock worth $1,062,000 after buying an additional 1,216 shares during the period. Royal Bank of Canada raised its stake in Alpine Immune Sciences by 99.1% during the 2nd quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 1,315 shares in the last quarter. American International Group Inc. boosted its position in Alpine Immune Sciences by 26.8% during the 2nd quarter. American International Group Inc. now owns 7,310 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 1,543 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Alpine Immune Sciences by 23.4% in the first quarter. JPMorgan Chase & Co. now owns 8,947 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 1,697 shares in the last quarter. Finally, California State Teachers Retirement System increased its holdings in shares of Alpine Immune Sciences by 20.0% during the second quarter. California State Teachers Retirement System now owns 10,559 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 1,763 shares during the period. Institutional investors own 75.17% of the company’s stock.

Alpine Immune Sciences Stock Performance

Alpine Immune Sciences stock opened at $64.37 on Monday. Alpine Immune Sciences, Inc. has a 1 year low of $6.71 and a 1 year high of $64.57. The firm’s 50 day moving average price is $36.42 and its two-hundred day moving average price is $23.12. The firm has a market cap of $4.22 billion, a price-to-earnings ratio of -100.58 and a beta of 1.14.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.47. Alpine Immune Sciences had a negative return on equity of 15.54% and a negative net margin of 54.66%. The business had revenue of $30.85 million for the quarter, compared to analysts’ expectations of $6.90 million. As a group, equities analysts predict that Alpine Immune Sciences, Inc. will post -1.74 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on ALPN. Wedbush lowered Alpine Immune Sciences from an “outperform” rating to a “neutral” rating in a report on Thursday. Morgan Stanley reissued an “equal weight” rating and set a $65.00 price target (up from $47.00) on shares of Alpine Immune Sciences in a report on Thursday. Oppenheimer reissued an “outperform” rating and set a $44.00 price target (up from $33.00) on shares of Alpine Immune Sciences in a report on Tuesday, March 19th. HC Wainwright lowered Alpine Immune Sciences from a “buy” rating to a “neutral” rating in a report on Thursday. Finally, SVB Leerink lowered Alpine Immune Sciences from an “outperform” rating to a “market perform” rating and raised their price target for the company from $42.00 to $65.00 in a report on Friday. Seven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Alpine Immune Sciences presently has a consensus rating of “Hold” and an average price target of $50.33.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.